C1QBP Antibody

What is C1QBP and why is it significant in research?

C1QBP (Complement Component 1, Q Subcomponent Binding Protein) is a multifunctional protein primarily localized in the mitochondria. It is synthesized as a 282 amino acid pro-protein that undergoes post-translational processing by removal of the initial 73 amino acids to form a mature 209 amino acid protein with a molecular weight of approximately 31.4 kDa . C1QBP is also known by several alternative names including gC1q-R, GC1QBP, HABP1, SF2AP32, and p32 .

The protein's significance stems from its diverse functions:

• Binding to globular heads of C1q molecules to inhibit C1 activation in the complement system

• Regulating mitochondrial morphology, metabolism, and autophagy

• Modulating cell proliferation, migration, and death/survival pathways

• Playing critical roles in tumor progression and immune cell function

This multifunctionality makes C1QBP antibodies essential tools for researching cellular processes ranging from basic mitochondrial function to complex disease mechanisms.

What applications are C1QBP antibodies commonly used for?

C1QBP antibodies are utilized across multiple experimental applications:

When selecting antibodies for specific applications, researchers should consider the validated applications listed for each commercial antibody. Many antibodies show cross-reactivity with human, mouse, and rat C1QBP, making them versatile for comparative studies across species .

How can researchers optimize Western blot protocols for C1QBP detection?

Optimizing Western blot protocols for C1QBP detection requires attention to several factors:

• Sample preparation:

  • For mitochondrial C1QBP, use mitochondrial isolation protocols to enrich for the target

  • Include protease inhibitors to prevent degradation of the 31.4 kDa protein

• Gel selection:

  • 10-12% polyacrylamide gels are typically suitable for resolving C1QBP's 32-35 kDa observed molecular weight

• Transfer conditions:

  • Semi-dry or wet transfer methods are both effective

  • Transfer buffer with 10-20% methanol typically works well

• Blocking and antibody dilutions:

  • Most C1QBP antibodies work effectively at dilutions between 1:5000-1:50000 for WB

  • Optimal blocking is typically 5% non-fat milk or BSA in TBST

• Validation controls:

  • Include positive controls from cells known to express C1QBP (e.g., HeLa, NIH/3T3, HEK-293)

  • When possible, include C1QBP knockdown/knockout samples as negative controls

Researchers have reported successful detection of C1QBP in various cell lines including C2C12, HEK-293, HCT 116, HeLa, K-562, NIH/3T3, PC-12, and RAW 264.7 cells .

What are the considerations for using C1QBP antibodies in immunohistochemistry?

When employing C1QBP antibodies for immunohistochemistry (IHC), researchers should consider:

• Antigen retrieval methods:

  • TE buffer at pH 9.0 is recommended for optimal epitope exposure

  • Alternatively, citrate buffer at pH 6.0 can be used

• Antibody selection factors:

  • For paraffin-embedded sections, antibodies validated for IHCP applications are essential

  • Monoclonal antibodies often provide more consistent results across experiments

• Dilution optimization:

  • Typical working dilutions range from 1:50-1:500

  • Titration experiments are recommended for each new tissue type

• Positive control tissues:

  • Human tonsillitis tissue and breast cancer tissue have shown consistent positive staining

  • C1QBP is highly expressed in cancer tissues, making them reliable positive controls

• Signal amplification:

  • For lower expression tissues, consider using polymer-based detection systems

  • Biotin-avidin systems may increase sensitivity but can introduce background

Additionally, C1QBP's subcellular localization should be considered when interpreting results. While primarily mitochondrial, C1QBP can also localize to the cell surface under certain conditions, which may result in different staining patterns .

How do monoclonal and polyclonal C1QBP antibodies compare in research applications?

The choice between monoclonal and polyclonal C1QBP antibodies significantly impacts experimental outcomes:

Research has demonstrated that epitope location can significantly impact antibody utility. For example, monoclonal antibody mAb-1 targets the first acidic loop of C1QBP and loses reactivity when this region is deleted, as confirmed by both Western blotting and surface plasmon resonance (SPR) .

For complex applications like structural analysis, monoclonal antibodies with well-characterized epitopes offer advantages for specific domain targeting. Conversely, polyclonal antibodies may be preferable for applications like immunoprecipitation where robust binding is needed .

How can C1QBP antibodies be utilized to study mitochondrial dynamics and plasticity?

C1QBP antibodies serve as powerful tools for investigating mitochondrial dynamics and plasticity through several methodologies:

• Co-localization studies:

  • Use C1QBP antibodies alongside mitochondrial markers (TOM20, MitoTracker) to assess changes in mitochondrial morphology

  • Confocal microscopy with immunofluorescence allows visualization of mitochondrial network reorganization in response to stimuli

• Mitochondrial isolation verification:

  • C1QBP antibodies can validate the purity of mitochondrial fractions in biochemical preparations

  • Western blotting of subcellular fractions with C1QBP antibodies confirms mitochondrial enrichment

• Dynamics monitoring in disease models:

  • Track changes in C1QBP distribution during conditions that alter mitochondrial function

  • Research has shown that C1QBP regulates mitochondrial morphology and metabolism, directly impacting tumor metastasis and therapeutic response

• Quantitative analysis in live cells:

  • Fluorescent-conjugated antibodies (e.g., CoraLite® Plus 488-conjugated anti-C1QBP) enable live-cell imaging of mitochondrial changes

  • Flow cytometry with permeabilized cells allows quantification of C1QBP levels in relation to mitochondrial mass

The regulatory role of C1QBP in mitochondrial plasticity makes these antibodies particularly valuable for cancer research, where mitochondrial adaptations significantly influence tumor progression and treatment response .

What role does C1QBP play in cancer progression and how can antibodies help investigate this?

C1QBP has been implicated in multiple aspects of cancer progression, with antibodies serving as critical tools for mechanistic investigation:

• Expression correlation with disease progression:

  • C1QBP upregulation has been documented in breast, lung, and colon cancer cell lines and tumors

  • C1QBP expression positively correlates with pathological stage and disease relapse in prostate cancer

• Metastasis mechanisms:

  • C1QBP promotes tumor metastasis by targeting epithelial-mesenchymal transition (EMT) markers and modulating the tumor microenvironment

  • C1QBP interacts with integrin αvβ3 to upregulate MT1-MMP expression and MMP-2 activation, enhancing cell migration in melanoma models

• Antibody-based inhibition studies:

  • C1QBP antibodies inhibit growth factor-stimulated lamellipodia formation, cell migration, and focal adhesion kinase activation

  • Antibody treatment prevents angiogenesis, offering potential therapeutic approaches

• Functional investigations:

  • Knockdown/knockout studies followed by antibody detection of downstream targets reveal C1QBP's influence on:

    • Cell proliferation (increases in normal and cancer cells)

    • Migration (promotes in multiple cell types)

    • Apoptosis resistance (protects against mitochondrial-driven death)

• Biomarker potential:

  • C1QBP serves as a tumor biomarker associated with lymph node and peritoneal metastasis in epithelial ovarian cancer

  • Immunohistochemistry with C1QBP antibodies enables prognostic assessment in clinical samples

Researchers investigating C1QBP in cancer should consider both genetic manipulation (knockdown/overexpression) combined with antibody-based detection of changes in expression, localization, and downstream pathway activation .

What considerations should be made when using C1QBP antibodies for T cell research?

When employing C1QBP antibodies in T cell research, investigators should address several specialized considerations:

• Mitochondrial fitness assessment:

  • C1QBP regulates T cells' mitochondrial metabolism and morphology, affecting their function

  • Antibodies can assess changes in C1QBP expression during T cell activation and differentiation

• Chimeric antigen receptor (CAR) T cell studies:

  • When investigating C1QBP+/+ versus C1QBP+/- CAR T cells, antibodies help confirm knockout/knockdown efficiency

  • Research has shown C1QBP's role in CAR T cell function against targets like huB7-H3

• Flow cytometry optimization:

  • For intracellular C1QBP detection in T cells, permeabilization protocols must be optimized

  • Recommended antibody concentration: ~0.80 μg per 10^6 cells in a 100 μl suspension

• Activation state considerations:

  • C1QBP expression and localization may change with T cell activation

  • Experimental timing is crucial when assessing C1QBP in relation to T cell stimulation

• Functional correlation experiments:

  • Combine C1QBP antibody detection with functional assays (cytokine production, proliferation)

  • C1QBP is involved in regulating immune cells' maturation, differentiation, and effector function through enhancement of mitochondrial function

T cell researchers should be aware that C1QBP manipulation affects the competitive balance between tumor cells and immune cells, making it relevant for immuno-oncology studies .

How can epitope mapping inform the selection of C1QBP antibodies for specific applications?

Epitope mapping provides crucial information for selecting C1QBP antibodies optimized for specific research applications:

• Structural considerations:

  • C1QBP contains distinct domains including acidic loops that serve as epitopes for various antibodies

  • Monoclonal antibody mAb-1 specifically recognizes the first acidic loop, while others like mAb-3, mAb-5, mAb-12, and mAb-18 react with multiple regions

• Application-specific selection:

  • For structural analysis: Antibodies targeting stable regions outside the acidic loops may provide more consistent results

  • For functional blocking: Antibodies targeting interaction domains (e.g., C1q binding region) are most effective

• Validation methods:

  • Western blotting with deletion mutants (e.g., gC1qR-D1, gC1q-D2, gC1qR-DD) can identify epitope locations

  • Surface plasmon resonance (SPR) provides quantitative data on binding kinetics for epitope-mapped antibodies

• Binding affinity considerations:

  • SPR analysis reveals that removal of certain regions (e.g., the second acidic loop) can enhance antibody binding to other epitopes

  • This information helps predict antibody performance in different experimental contexts

• Commercial antibody information:

  • Many suppliers provide detailed epitope information:

    • Antibodies targeting middle regions (e.g., Aviva Systems Biology)

    • Antibodies recognizing AA 76-282 or other specific domains

Researchers should leverage epitope mapping data to select antibodies that will maintain reactivity under their specific experimental conditions, especially when studying modified, truncated, or conformationally altered forms of C1QBP.

What are the common challenges in C1QBP antibody applications and how can they be addressed?

Researchers frequently encounter specific challenges when working with C1QBP antibodies:

• Subcellular localization variability:

  • Challenge: C1QBP primarily localizes to mitochondria but can also appear at the cell surface and in other compartments

  • Solution: Use subcellular fractionation followed by Western blotting to confirm localization, or co-staining with compartment markers for microscopy approaches

• Cross-reactivity with related proteins:

  • Challenge: Potential cross-reactivity with other complement-related proteins

  • Solution: Validate specificity through knockout/knockdown controls; select antibodies with demonstrated low cross-reactivity (e.g., <1% cross-reactivity with recombinant human C1QR)

• Post-translational modifications:

  • Challenge: C1QBP undergoes processing from a 282aa pro-protein to a 209aa mature form

  • Solution: Select antibodies recognizing appropriate regions depending on whether you're studying the precursor or mature form

• Background in immunohistochemistry:

  • Challenge: High background due to endogenous biotin or non-specific binding

  • Solution: Use non-biotin detection systems and optimize antigen retrieval (TE buffer pH 9.0 recommended)

• Variable expression levels:

  • Challenge: C1QBP expression varies significantly across cell types and disease states

  • Solution: Include positive controls with known expression (e.g., cancer cell lines) and optimize exposure times/antibody dilutions accordingly

For antibody validation, researchers should implement genetic approaches (siRNA, CRISPR knockout) alongside traditional controls to ensure signal specificity, particularly in complex samples or specialized cell types.

How can researchers effectively validate the specificity of C1QBP antibodies?

Rigorous validation of C1QBP antibody specificity requires a multi-faceted approach:

• Genetic validation strategies:

  • Generate C1QBP knockdown or knockout models using siRNA, shRNA, or CRISPR-Cas9

  • Confirm signal reduction/elimination with the antibody in question

  • Published studies demonstrate successful validation using stable knockdown of C1QBP by shRNA in cancer cell lines

• Multiple antibody comparison:

  • Test multiple antibodies targeting different epitopes of C1QBP

  • Concordant results across antibodies increase confidence in specificity

  • Differential reactivity to C1QBP deletion mutants can help characterize epitope specificity

• Recombinant protein controls:

  • Use purified recombinant C1QBP as a positive control

  • Pre-absorption of antibody with recombinant protein should eliminate specific signal

• Mass spectrometry verification:

  • Immunoprecipitate C1QBP and confirm identity by mass spectrometry

  • This approach validates both antibody specificity and potential interaction partners

• Application-specific validation methods:

  • For IHC: Compare staining patterns with mRNA expression data (e.g., ISH)

  • For WB: Confirm band appears at expected molecular weight (32-35 kDa observed)

  • For IP: Verify pulled-down protein by Western blot with a different C1QBP antibody

Comprehensive validation should include positive and negative controls relevant to the experimental system, and careful documentation of antibody details including catalog number, lot, and dilution used for reproducibility.

What parameters should be considered when optimizing immunoprecipitation using C1QBP antibodies?

Successful immunoprecipitation (IP) of C1QBP requires attention to several critical parameters:

• Antibody selection criteria:

  • Choose antibodies specifically validated for IP applications

  • Examples include Bethyl Laboratories' Rabbit anti-C1QBP (validated for WB, IHC, IP)

  • Consider antibody affinity – higher affinity generally yields better IP results

• Lysis buffer optimization:

  • For mitochondrial C1QBP: Use buffers compatible with mitochondrial extraction

  • Typical effective buffer: 20 mM HEPES (pH 7.4), 140 mM NaCl, 0.1% detergent

  • Include protease inhibitors to prevent degradation during extraction

• Cross-linking considerations:

  • For transient interactions: Consider chemical cross-linking (e.g., DSP, formaldehyde)

  • For stable complexes: Standard IP without cross-linking may be sufficient

• Binding and elution conditions:

  • Incubation time: Typically 2-4 hours at 4°C or overnight for maximum recovery

  • Washing stringency: Balance between removing non-specific binding and preserving specific interactions

  • Elution method: Low pH glycine (0.1 M, pH 2.2) has been used successfully in C1QBP studies

• Validation approaches:

  • Confirm IP efficiency by Western blotting a portion of input, unbound, and eluted fractions

  • For protein-protein interaction studies, consider reciprocal IP with antibodies against potential interaction partners

For competition binding assays, researchers have successfully employed AlphaScreen bead-based methods to evaluate interactions between anti-C1QBP monoclonal antibodies and chemically biotinylated C1QBP, providing quantitative data on binding specificity .

How might C1QBP antibodies be utilized in developing novel cancer therapeutics?

C1QBP antibodies show promising potential for cancer therapeutic development through several mechanisms:

• Targeted therapy approaches:

  • C1QBP has been identified as a receptor for nanoparticle drugs (CGKRK nanoworms) effective against orthotopic glioblastoma and breast cancer

  • Antibodies could be used to validate target engagement in preclinical models

• Diagnostic and prognostic applications:

  • C1QBP expression correlates with cancer progression, making antibody-based detection valuable for patient stratification

  • IHC analysis using C1QBP antibodies can help identify patients with lymph node and peritoneal metastasis in epithelial ovarian cancer

• Functional blocking strategies:

  • C1QBP antibodies inhibit lamellipodia formation, cell migration, and focal adhesion kinase activation

  • These functional effects suggest direct therapeutic potential through blocking C1QBP's pro-tumor activities

• Combined immunotherapy approaches:

  • C1QBP regulates immune cell function, making it relevant for immuno-oncology

  • Antibodies can help evaluate how C1QBP manipulation affects the balance between tumor and immune cells

• Delivery system development:

  • C1QBP-targeted delivery systems could improve drug specificity

  • Antibodies conjugated to nanoparticles or liposomes might enhance therapeutic payload delivery to cancer cells

Research has demonstrated that manipulation of C1QBP modulates the tumor microenvironment through inhibiting tumor angiogenesis and macrophage infiltration, suggesting multiple potential intervention points for antibody-based therapeutics .

What is the significance of studying C1QBP in mitochondrial dysfunction disorders?

C1QBP's critical role in mitochondrial function makes it an important research target for mitochondrial disorders:

• Genetic disorder connections:

  • C1QBP is associated with COXPD33 (combined oxidative phosphorylation deficiency 33)

  • Antibodies enable analysis of C1QBP expression and localization in patient samples

• Mitochondrial morphology regulation:

  • C1QBP regulates mitochondrial morphology, which is frequently altered in mitochondrial diseases

  • Antibody-based imaging allows assessment of mitochondrial network structure in relation to C1QBP expression

• Metabolism and energy production:

  • Studies show C1QBP knockdown increases cellular ATP levels

  • This counterintuitive finding warrants further investigation in mitochondrial disease contexts

• Quality control mechanisms:

  • C1QBP plays a role in mitochondrial autophagy (mitophagy)

  • Antibodies can track C1QBP dynamics during mitophagy processes in disease models

• Therapeutic target potential:

  • Understanding C1QBP's function may reveal new therapeutic approaches for mitochondrial disorders

  • Antibodies serve as essential tools for target validation and mechanism studies

Researchers investigating mitochondrial disorders should consider C1QBP as a key regulator of mitochondrial plasticity that impacts various aspects of mitochondrial function beyond its better-known role in complement binding.

The mitochondrial localization of C1QBP makes it particularly relevant for studying diseases with mitochondrial dysfunction, including neurodegenerative disorders, metabolic diseases, and aging-related pathologies where mitochondrial dynamics play crucial roles.